Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Atara Biotherapeutics Inc    ATRA

ATARA BIOTHERAPEUTICS INC (ATRA)
Add to my list  
Mes dernières consult.
Most popular
Manage my lists
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
39.3(c) 41.2(c) 41.35(c) 39.4(c) 39.5(c) Last
503 870 370 673 408 524 303 578 252 055 Volume
-3.20% +4.83% +0.36% -4.72% +0.25% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -157 M
Net income 2018 -151 M
Finance 2018 417 M
Yield 2018 -
Sales 2019 2,98 M
EBIT 2019 -194 M
Net income 2019 -183 M
Finance 2019 388 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 441x
Capitalization 1 703 M
More Financials
Company
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.Its product candidates are biologics targeting myostatin and activin, members of the... 
Read more
More about the company
Surperformance© ratings of Atara Biotherapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ATARA BIOTHERAPEUTICS INC
04/09Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 563..
GL
03/22ATARA BIOTHERAPEUTICS : to Participate in Three Upcoming Immuno-Oncology Confere..
AQ
03/22Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Confer..
GL
03/16Atara Biotherapeutics to Present at the 44th Annual Meeting of the European S..
GL
03/06Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health ..
GL
03/05ATARA BIOTHERAPEUTICS, INC. (NASDAQ : ATRA) Files An 8-K Financial Statements an..
AQ
03/02ATARA BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
03/01ATARA BIOTHERAPEUTICS : raises another $150M in latest follow-on
AQ
03/01Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
GL
02/28ATARA BIOTHERAPEUTICS : Announces Proposed Offering of Common Stock
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/18$ATRA may be ready to launch (weekly)
8
04/13$ATRA - Analysts Anticipate Atara Biotherapeutics #ATRA Will Announce Earning.. 
04/12Somewhat Favorable News Coverage Somewhat Unlikely to Impact Atara Biotherape.. 
04/11$ATRA Weekly. Essence of relative strength in sloppy biotech sector last few ..
8
04/10$ATRA up 7% this morning, Bio name with 5K June $40 calls in OI from steady a..
2
More tweets
Qtime:129
News from SeekingAlpha
04/19READER INQUIRY : What's The Outlook For Atara Biotherapeutics After The Recent S.. 
04/15PORTFOLIO REVIEW : Continued Market Outperformance In Q1 2018 
04/13Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned 
04/13ROUNDS REPORT : Geron Rallied While FDA's New Guidance Created Tailwinds For Ind.. 
04/10Premarket analyst action - healthcare 
Chart ATARA BIOTHERAPEUTICS INC
Duration : Period :
Atara Biotherapeutics Inc Technical Analysis Chart | ATRA | US0465131078 | 4-Traders
Technical analysis trends ATARA BIOTHERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 46,6 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Issac E. Ciechanover Chairman, President & Chief Executive Officer
John F. McGrath Chief Financial Officer & Executive Vice President
Christopher M. Haqq Chief Scientific Officer, Executive VP-R&D
Joe Newell Chief Technical Operations Officer & Executive VP
Kanya Rajangam Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ATARA BIOTHERAPEUTICS INC118.23%1 703
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998
4-traders.com :
About :
Stay Connected :
Partners :
Copyright © 2018 Surperformance. All rights reserved.